AbbVie Price Target, Predictions & Analyst Ratings

+0.20 (+0.19 %)
(As of 09/16/2021 02:35 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume252,797 shs
Average Volume7.02 million shs
Market Capitalization$190.80 billion
P/E Ratio29.10
Dividend Yield4.88%

AbbVie (NYSE:ABBV) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Based on 16 Analyst Ratings

Analyst Price Target Consensus


High PT$142.00
Average PT$124.15
Low PT$98.00
9/16/20 to 9/16/21
1 Month Ago
8/17/20 to 8/17/21
3 Months Ago
6/18/20 to 6/18/21
1 Year Ago
9/17/19 to 9/16/20
Consensus Rating
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
13 Buy rating(s)
13 Buy rating(s)
11 Buy rating(s)
13 Buy rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$124.15$122.58$120.33$108.33
Price Target Upside14.98% Upside15.02% Upside21.08% Upside17.85% Upside
Get AbbVie Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AbbVie (NYSE:ABBV) vs. Its Competitors

TypeAbbVieMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingBuyBuyBuy
Price Target Upside126.19% Upside7.50% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
Community Rating
Outperform Votes
Underperform Votes
Avg. Outperform Votes
Avg. Underperform Votes
Avg. Outperform Votes
Avg. Underperform Votes

AbbVie (NYSE:ABBV) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/2/2021SVB Leerink
Geoff Porges
Lower Price TargetOutperform$148.00 ➝ $142.00+26.48%
Boost Price TargetOutperform$120.00 ➝ $130.00+9.23%
8/20/2021Morgan Stanley
Matthew Harrison
Reiterated RatingBuy$116.00-2.37%
David Toung
Boost Price TargetBuy ➝ Buy$130.00 ➝ $140.00+21.64%
Boost Price TargetBuy$128.00 ➝ $131.00+12.64%
Boost Price TargetEqual Weight$105.00 ➝ $112.00-3.70%
7/27/2021Truist Securities
Initiated CoverageBuy$117.00-0.87%
7/2/2021Daiwa Capital Markets
Initiated CoverageOutperform
5/3/2021BMO Capital Markets
Boost Price TargetOutperform$127.00 ➝ $129.00+15.70%
4/30/2021Piper Sandler
Boost Price TargetOverweight$120.00 ➝ $124.00+11.21%
4/7/2021Royal Bank of Canada
Initiated Coverage$135.00+28.94%
11/10/2020Sanford C. Bernstein
Initiated CoverageOutperform$120.00+26.16%
10/20/2020The Goldman Sachs Group
DowngradeNeutral ➝ Sell
10/16/2020JPMorgan Chase & Co.
Boost Price TargetOverweight$115.00 ➝ $120.00+40.19%
9/29/2020Berenberg Bank
Initiated CoverageHold$98.00+12.28%
Boost Price TargetBuy$98.00 ➝ $105.00+13.50%
6/23/2020Atlantic Securities
UpgradeNeutral ➝ Overweight$115.00+18.23%
6/17/2020UBS Group
Boost Price Target$96.00 ➝ $109.00+13.52%
6/10/2020Evercore ISI
Joshua Schimmer
Initiated CoverageBuy$111.00+14.55%
6/9/2020Wolfe Research
UpgradePeer Perform ➝ Outperform
5/18/2020Bank of America
Initiated CoverageNeutral$95.00+4.73%
3/23/2020Societe Generale
DowngradeBuy ➝ Hold
11/1/2019Piper Jaffray Companies
Christopher Raymond
Boost Price Target$81.00 ➝ $90.00+10.09%
4/26/2019Credit Suisse Group
Vamil Divan
Set Price TargetSell$78.00-2.00%
12/26/2018Standpoint Research
Initiated CoverageBuy ➝ Buy
10/22/2018SunTrust Banks
Lower Price TargetBuy ➝ Buy$157.00 ➝ $135.00+58.71%
(Data available from 9/16/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)
speech bubbles
speech bubbles

AbbVie (NYSE:ABBV) Analyst Ratings Frequently Asked Questions

What is AbbVie's consensus rating and price target?

According to the issued ratings of 16 analysts in the last year, the consensus rating for AbbVie stock is Buy based on the current 1 sell rating, 2 hold ratings and 13 buy ratings for ABBV. The average twelve-month price target for AbbVie is $124.15 with a high price target of $142.00 and a low price target of $98.00. Learn more on ABBV's analyst rating history

Do Wall Street analysts like AbbVie more than its competitors?

Analysts like AbbVie stock more than the stock of other Medical companies. The consensus rating score for AbbVie is 2.75 while the average consensus rating score for medical companies is 2.73. Learn more on how ABBV compares to other companies

Do MarketBeat users like AbbVie more than its competitors?

MarketBeat users like AbbVie stock more than the stock of other Medical companies. 74.32% of MarketBeat users gave AbbVie an outperform vote while medical companies recieve an average of 67.17% outperform votes by MarketBeat users.

Does AbbVie's stock price have much upside?

According to analysts, AbbVie's stock has a predicted upside of 13.57% based on their 12-month price targets.

What analysts cover AbbVie?

AbbVie has been rated by Argus, Barclays, Cowen, Daiwa Capital Markets, Mizuho, Morgan Stanley, SVB Leerink, Truist, and Truist Securities in the past 90 days.

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.